Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

Novartis Sees Reimbursement Advantage For PCSK9 Launch

Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.

Reimbursement Business Strategies

For An Ultra-High-Priced Drug, Alnylam Brings A New Idea

The company will launch Givlaari with a novel prevalence-based adjustment feature for payers, which will trigger higher rebates if the number of diagnosed patients is higher than expected. 
Rare Diseases Pricing Strategies

Vertex Versus NHS England: Was The Stand-Off Worth It?

After three years as the pharma bogeyman, Vertex has agreed a deal in England. So what purpose did the stand-off serve?

United Kingdom Commercial

Vertex Finally Inks Orkambi Deal In England

Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.

Companies Reimbursement

Gene Therapy Manufacturing Hitch Solved, Bluebird Aims For European Debut In 2020

The EMA has declared itself satisfied with ‘refined manufacturing specifications’ for the beta thalassemia treatment

Regulation Gene Therapy

Biopharma Can Live With Boris’s Brexit Deal – But Will It Pass?

Industry would settle for UK Prime Minister Boris Johnson’s deal, with sweeteners promised for the sector.
United Kingdom Commercial

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.
Gene Therapy Reimbursement

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Reimbursement Market Access

Bayer's Vitrakvi Is EU’s First Tumor-Agnostic Treatment

The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.

Approvals Cancer
See All
UsernamePublicRestriction

Register